A randomised comparison of safety and efficacy of triple therapy for 12 weeks, followed by 12 or 36 additional weeks of peginterferon alfa 2b and ribavirin in HCV patients
Phase 3
- Conditions
- Chronic hepatitis C
- Registration Number
- JPRN-UMIN000006952
- Lead Sponsor
- Hiroshima liver study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 230
Inclusion Criteria
Not provided
Exclusion Criteria
1)Transient response to prior treatment 2)Patients receiving shosaiko-to 3)Autoimmune hepatitis 4)History of hypersensitivity to PEG-IFN alpha-2b and telaprevir 5)History of hypersensitivity to biological products such as vaccine 6)Decompenstated liver cirrhosis 7)HCC, malignat tumor 8)With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. 9)Pregnant or lactating women and women who may be pregnant 10)Judged by investigator not to be appropriate for inclusion in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method